Stay updated with breaking news from Bridgebio Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sectoral Asset Management Inc. cut its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 92.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,955 shares of the company’s stock after selling 167,240 shares during the quarter. Sectoral […]
Sectoral Asset Management Inc. cut its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 92.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,955 shares of the company’s stock after selling 167,240 shares during the quarter. Sectoral […]
PALO ALTO, Calif., June 03, 2024 -- BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of its management team, along...
Cantor Fitzgerald restated their overweight rating on shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) in a report issued on Tuesday morning, Benzinga reports. They currently have a $70.00 price target on the stock. Other equities analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. raised their price target on […]
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) and Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends. Valuation and Earnings This table compares BridgeBio […]